What Arflur-P Treats: Main Uses and Benefits

Arflur-P is generally applied across domains where additional symptomatic support is needed, primarily focusing on symptoms related to physical discomfort and inflammatory or irritative states. This medication is considered relevant for managing pain and inflammation in a wide range of conditions.

This combination is commonly used across conditions presenting with acute episodes, such as managing symptomatic distress in Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, and acute musculoskeletal disorders. Its use extends to short-term relief for issues like low back pain, sprains and strains, and post-procedure pain (e.g., following a dental extraction or for menstrual pain).

The combination is used for managing symptom clusters that may become intense or disruptive, specifically when pain and inflammation are accompanied by fever. “It offers symptomatic relief that helps patients cope more steadily when these symptoms become more noticeable.” This integrated action provides support that helps ease the overall symptom burden, assisting with maintaining functional stability during symptomatic periods.

Quick Fact: Symptomatic Support for Pain, Inflammation, and Fever
Main Use Context	Acute episodes of inflammatory joint disorders and musculoskeletal discomfort.
Primary Benefit	Supports the easing of pain and inflammation, and contributes to fever reduction.
Severity Relevance	Symptomatic management for mild to moderate discomfort.

Who can and cannot use Arflur-P?

Regulatory agencies define the eligibility for Arflur-P, a combination of an NSAID and Paracetamol, through strict rules governing patient health status and age.

Populations for Whom Use is Contraindicated
Patients with hypersensitivity to Aceclofenac, Paracetamol, or other NSAIDs (which induce asthma, rhinitis, or urticaria).
Individuals with active or history of recurrent peptic ulcer/haemorrhage.
Patients with severe heart failure, severe hepatic impairment, or severe renal impairment.
Individuals with established arterial disease (ischaemic heart, peripheral arterial, or cerebrovascular disease).
Third trimester of pregnancy.

Age and Reproductive Eligibility: The medicine is generally approved for Adults. It is not recommended for use in children and adolescents under 18 years of age due to insufficient clinical data. Use during the first two trimesters of pregnancy and while breastfeeding is generally not recommended.

Conditional Use: The medicine requires close medical surveillance for the elderly and for patients with mild-to-moderate impairment of renal or hepatic function, or a history of specific gastrointestinal conditions like Crohn's disease.

Interactions with other medicines and products

Official regulatory information for Arflur-P (Aceclofenac + Paracetamol) documents several categories of interactions, primarily classified by their effect on drug exposure or cumulative toxicity risk. Factual information on these interaction patterns is based on governmental prescribing documents.

Contraindicated Combinations

Co-administration is prohibited with other NSAIDs (including COX-2 selective inhibitors) and other Paracetamol-containing products due to the documented risk of severe cumulative gastrointestinal and hepatic toxicity.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Category	Interacting Agents	Officially Documented Outcome
Exposure-Altering	Lithium, Digoxin, Methotrexate	May result in increased serum concentrations of these agents due to reduced renal clearance.
Anticoagulants	Warfarin	Increased risk of bleeding due to pharmacodynamic enhancement of the anticoagulant effect.
Risk Agents	Corticosteroids, SSRIs	Increased risk of gastrointestinal bleeding when combined with the Aceclofenac component.
Antihypertensives	ACE-inhibitors, Diuretics	May reduce the blood pressure-lowering effect and increase the risk of acute renal insufficiency.

Substance and Timing Constraints

Official labeling documents a constraint regarding Alcohol (Ethanol), stating that consumption of three or more drinks daily may increase the risk of severe liver damage from the Paracetamol component. A timing-based restriction applies to Mifepristone; NSAIDs must not be used for 8–12 days following its administration, as this may reduce its effectiveness. The risk of Paracetamol toxicity may also be increased by concomitant use of hepatic enzyme inducers, such as Rifampicin.

Targeting Mediator Synthesis via Enzyme Inhibition

The Aceclofenac component acts primarily by inhibiting Cyclooxygenase (COX) enzymes within the arachidonic acid cascade. This action modifies early molecular steps by limiting the synthesis of specific prostaglandins, lipid mediators that govern pathway activity associated with heightened physiological responses. This mechanistic domain engages processes that regulate overactive local responses, thereby modulating the downstream effects of excessive mediator activity.

Operating Within Central Thermoregulatory and Pain Pathways

The Paracetamol component operates within a distinct mechanistic domain by modulating the activity of the Central Nervous System (CNS). It is thought to influence signaling and acts on the hypothalamic heat-regulating center. This targeted pathway adjustment facilitates a more regulated state within targeted central pathways, influencing neural mechanisms associated with thermoregulation and afferent signal processing.

The Complementary Dual-Action Mechanism

The drug employs a combined, complementary approach, influencing biological systems where targeted pathway adjustment occurs across different physiological compartments. It modifies early molecular steps to modulate peripheral mediator signaling (Aceclofenac) while concurrently adjusting signaling dynamics within central pathways (Paracetamol). This synergistic effect influences the regulation of overactive physiological responses across two key mechanistic domains.

Arflur-P is administered exclusively by the oral route as a film-coated tablet. The administration protocol requires the tablet to be swallowed whole with fluid; crushing or chewing is not permitted. A key instruction is the timing relative to meals: the dose should be taken preferably with or immediately after food, which is intended to ensure proper administration conditions.

The standard administration schedule for adults dictates taking one tablet twice daily (e.g., in the morning and evening). This frequency is established to maintain an appropriate interval between the 100 mg Aceclofenac doses, setting the total maximum daily intake for the combination at two tablets. The overarching principle governing the duration of use is to employ the lowest effective dose for the shortest time necessary to achieve the desired symptomatic support.

Procedural adjustments apply for certain populations. Patients diagnosed with mild to moderate hepatic impairment require a reduction in the initial dose frequency, typically to one tablet taken only once daily. Conversely, no specific dose modification is required for older adults. The medicine is not recommended for use in the pediatric population.

Research Evidence / Overview of Studies for Arflur-P

This section provides a factual overview of the types of research conducted on Arflur-P (Aceclofenac and Paracetamol combination), or its components. It describes what the studies explored and the patterns observed, while maintaining transparency about what is still uncertain.

Evidence for Symptomatic Relief of Pain and Inflammation

Research relevant to this combination has primarily involved short-to-intermediate-term Randomized Controlled Trials (RCTs) and related studies on adults with conditions like Osteoarthritis and Rheumatoid Arthritis. Researchers explored outcomes related to physical discomfort and daily functioning. Findings describe patterns observed in studies where the measurements of outcomes were recorded and evaluated over short periods (a few weeks to months). It is important to note that study results reflect the specific conditions and populations under which they were conducted, and findings describe group patterns, not personal outcomes.

Evidence for Reduction of Fever

Research exploring fever reduction largely centers on the Paracetamol component, which has a long history of study for this use. Studies observed how body temperature changed in adult and pediatric groups, monitoring the degree and duration of temperature change. The evidence is part of the existing body of research for antipyretic agents, with data showing patterns related to acute changes. Comparative evidence is lacking for the specific contribution of Aceclofenac to fever reduction when used in this combination.

Long-Term Studies, Special Populations, and Uncertainty

Long-term effects are not fully established, as follow-up durations were limited in many primary trials, meaning sustained outcomes over years are uncertain. Research was observed in some adult populations, including older adults, but data for certain groups remain insufficient, particularly pregnant individuals and patients with severe kidney or liver impairment. The research overall provides context but not individual predictions, and certainty remains low regarding specific long-term and comparative outcomes.

Common questions about Arflur-P (FAQ)

Q: Why do some people say Arflur-P is 'stronger' than a regular over-the-counter pill?

A: The official product information describes Arflur-P as a fixed-dose combination, meaning it contains two active ingredients: an NSAID (Aceclofenac) and Paracetamol. The Aceclofenac component is often categorized as a prescription-only medicine due to its effects, and the combined formula is intended to influence both central pain pathways and peripheral inflammation.

Q: Is Arflur-P safe for older adults, according to regulatory information?

A: Regulatory information indicates that no specific dose modification is required for older patients. However, official warnings note that older adults may have an increased frequency of adverse reactions, particularly severe gastrointestinal events. For this reason, regulatory documents note that close medical surveillance is required for this population.

Q: Are there any specific foods or beverages that interact with Arflur-P?

A: Official information specifies that alcohol must be avoided due to a documented increased risk of severe liver damage from the Paracetamol component. Regarding administration, official administration guidelines indicate the dose is taken with or immediately after food to minimize potential gastrointestinal discomfort.

Q: Can Arflur-P be taken if I have high blood pressure?

A: Official product information states the medicine is contraindicated (should not be used) in patients with established congestive heart failure. For individuals with a history of hypertension (high blood pressure), regulatory information notes that caution and monitoring may be required, as fluid retention and swelling have been reported with NSAIDs.

Q: Can Arflur-P be used for headaches or only for chronic pain?

A: Regulatory documents state the medicine is for the relief of pain and inflammation, and for reducing fever. The indications often include common acute pain types like headache and dental pain in patient leaflets for the combined components, confirming its use beyond chronic conditions.

Q: Do studies show Arflur-P is better tolerated than other similar medicines?

A: Regulatory documents generally describe the product's efficacy and safety profile for its indicated use. However, they typically do not contain explicit, official comparative claims of superiority regarding tolerance or effectiveness against other specific medicines.

Q: Is it possible to take Arflur-P while also taking an antidepressant?

A: Official documents list specific interactions. For antidepressants, co-administration with SSRIs (a type of antidepressant) is documented as having an increased risk of gastrointestinal bleeding. Information regarding other specific classes of antidepressants is generally not provided explicitly.

Q: What are the official warning signs listed for a serious side effect of Arflur-P?

A: Serious adverse reactions described in regulatory documents include gastrointestinal bleeding, severe liver damage, and serious skin reactions. Official warnings describe that signs associated with these events may include black or tarry stools, sudden stomach pain, or yellowing of the skin or eyes (jaundice).

Q: Are there different strengths of Arflur-P available?

A: The product is a fixed-dose combination with a single strength primarily specified in its official leaflet. This typically involves Aceclofenac 100 mg combined with a standard dose of Paracetamol.

Q: What is the maximum duration of use recommended in the product monograph for Arflur-P?

A: The official product information states the principle of using the lowest effective dose for the shortest duration necessary to achieve symptomatic relief. A universal maximum duration for all uses is not always specified in the product monograph, as it depends on the condition being treated.

Q: Does Arflur-P contain an opioid?

A: Official regulatory documents confirm the active ingredients are Aceclofenac (an NSAID) and Paracetamol (an analgesic/antipyretic). The product does not list any opioid component in this fixed-dose combination.

Q: How quickly does Arflur-P typically start to work?

A: Regulatory information indicates that the Paracetamol component is rapidly absorbed, with peak concentrations typically reached within 30 minutes to 2 hours. Aceclofenac peak concentrations are generally reached within 1.25 to 3 hours, suggesting a relatively rapid onset of pain relief.

Q: Is it normal to feel a bit drowsy after taking Arflur-P?

A: Yes, official regulatory documents list dizziness, drowsiness (somnolence), and visual disturbances as potential adverse effects. Regulatory documents note that if these effects occur, caution related to activities like driving may be necessary.

Q: Does taking Arflur-P affect my ability to drive?

A: Official regulatory documents state that due to the potential for side effects such as dizziness, drowsiness, or visual disturbances, caution is required, and activities like driving or operating heavy machinery should be avoided if these symptoms are experienced.

Q: Why is Arflur-P only available by prescription?

A: The product contains the NSAID Aceclofenac (100 mg), a component that regulatory authorities typically categorize as a prescription-only medicine. This status is assigned because the medicine’s known risks require medical supervision to ensure appropriate use.

Q: What is the difference between Arflur-P and the standard 'Arflur' version?

A: The standard 'Arflur' version generally contains only the anti-inflammatory component, Aceclofenac. The 'Arflur-P' designation is used by the manufacturer to denote the fixed-dose combination that includes both Aceclofenac and Paracetamol (Acetaminophen).

Q: Does Arflur-P have a potential for dependency?

A: The active ingredients are an NSAID and an analgesic/antipyretic, neither of which are classified as addictive substances. Withdrawal or dependency issues are not listed among the recognized adverse reactions in the official safety profile.

Q: Can Arflur-P cause changes in mood or sleep patterns?

A: Regulatory documents list central nervous system (CNS) adverse effects such as dizziness and, rarely, visual disturbances. Changes to mood or sleep patterns are generally not listed as common or uncommon adverse reactions in the official safety data.

Q: What is the typical duration of effect for a dose of Arflur-P?

A: The typical recommended dosing frequency for this combination is twice daily (two times a day). This frequency indicates that the therapeutic effect is intended to last approximately 12 hours to maintain consistent symptom relief.

Q: What does the P in Arflur-P stand for?

A: The 'P' in the brand name is a common pharmaceutical naming convention used by the manufacturer to denote the presence of the Paracetamol (Acetaminophen) component in the fixed-dose combination.

Q: Is Arflur-P known to cause water retention or swelling?

A: Yes, regulatory documents for the Aceclofenac component note that fluid retention and oedema (swelling) have been reported in association with NSAID therapy. Regulatory documents state that appropriate monitoring is required, particularly for patients with a history of hypertension or heart failure.

Q: How is Arflur-P absorbed and processed by the body?

A: Regulatory information describes that both active components are rapidly absorbed from the gastrointestinal tract. They are then primarily processed (metabolized) by the liver before being excreted from the body, largely through the urine.

Q: Does Arflur-P affect how other medicines are absorbed?

A: Official regulatory information typically focuses on how Arflur-P can affect the levels of other medicines in the blood by reducing renal clearance or competitive metabolism. Direct evidence of altered absorption of other drugs is not typically detailed in the interactions list.

Q: Is it necessary to have routine blood tests while on Arflur-P?

A: Regulatory documents state that individuals receiving long-term treatment require regular monitoring of renal function tests, liver function tests, and blood counts.

Q: Are there any officially listed withdrawal effects from stopping Arflur-P?

A: Withdrawal effects are not listed as recognized adverse reactions or consequences of stopping the treatment in the official safety profile for this NSAID/Analgesic combination.

Q: Can I use Arflur-P if I have diabetes?

A: Diabetes itself is not listed as a contraindication. However, regulatory documents list interactions with medicines used to lower blood sugar levels. Due to the potential for effects on kidney function, regulatory documents indicate that close monitoring may be required.

Official Storage and Disposal Instructions

Arflur-P (Aceclofenac and Paracetamol) must be stored in compliance with the conditions specified on the official product labeling to maintain its stability and effectiveness. The medicine must be kept at a controlled temperature, typically below 30°C, in a cool and dry place.

Storage Requirements

Condition	Requirement
Temperature	Below 30°C
Protection	Protect from light and moisture
Container	Keep in original, tightly closed container
Safety	Store out of the sight and reach of children

Disposal

Do not use Arflur-P after its printed expiry date. Unused or expired medication should be disposed of safely, ideally through a certified drug take-back program or pharmacy collection point. To prevent environmental contamination, the product should not be flushed down the toilet or disposed of in wastewater.